{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T13:35:59Z","timestamp":1785677759456,"version":"3.56.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00292-024-01317-6","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T10:02:07Z","timestamp":1712138527000},"page":"309-315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mesothelioma: morphologic and immunohistochemical findings","Mesotheliom: morphologische und immunhistochemische Befunde"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4851-8517","authenticated-orcid":false,"given":"Andrew","family":"Churg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"1317_CR1","doi-asserted-by":"crossref","unstructured":"Churg A (2024) New developments in mesothelial pathology. Histopathology 84:136\u2013152","DOI":"10.1111\/his.15007"},{"key":"1317_CR2","volume-title":"Thoracic tumors","author":"WHO Classification of Tumors Editorial Board","year":"2021","unstructured":"WHO Classification of Tumors Editorial Board (2021) Thoracic tumors. International Agency for Research on Cancer, Lyon"},{"key":"1317_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/his.14127","volume":"77","author":"YZ Zhang","year":"2020","unstructured":"Zhang\u00a0YZ, Brambilla\u00a0C, Molyneaux\u00a0PL et\u00a0al (2020) Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2\u2011tier nuclear grade. Histopathology 77:423\u2013436","journal-title":"Histopathology"},{"key":"1317_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","volume":"4","author":"YP Hung","year":"2018","unstructured":"Hung\u00a0YP, Dong\u00a0F, Watkins\u00a0JC et\u00a0al (2018) Identification of ALK rearrangements in malignant peritoneal mesothelioma. JAMA Oncol 4:235\u2013238","journal-title":"JAMA Oncol"},{"key":"1317_CR5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jtho.2018.04.023","volume":"13","author":"F Galateau Salle","year":"2018","unstructured":"Galateau Salle\u00a0F, Le Stang\u00a0N, Nicholson\u00a0AG et\u00a0al (2018) New insights on diagnostic reproducibility of biphasic mesotheliomas: a\u00a0multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center. J\u00a0Thorac Oncol 13:1189\u20131203","journal-title":"J Thorac Oncol"},{"key":"1317_CR6","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1002\/cncr.32416","volume":"125","author":"LR Chirieac","year":"2019","unstructured":"Chirieac\u00a0LR, Hung\u00a0YP, Foo\u00a0WC, Hofer\u00a0MD, VanderLaan\u00a0PA, Richards\u00a0WG, Sugarbaker\u00a0DJ, Bueno\u00a0R et\u00a0al (2019) Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. Cancer 125:4164\u20134171","journal-title":"Cancer"},{"key":"1317_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/his.15065","author":"JJ Schulte","year":"2023","unstructured":"Schulte\u00a0JJ, Husain\u00a0AN (2023) Updates on grading mesothelioma. Histopathology. https:\/\/doi.org\/10.1111\/his.15065 (Epub ahead of print. PMID: 37872123)","journal-title":"Histopathology"},{"key":"1317_CR8","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/PAS.0000000000000696","volume":"40","author":"K Valente","year":"2016","unstructured":"Valente\u00a0K, Blackham\u00a0AU, Levine\u00a0E et\u00a0al (2016) A Histomorphologic grading system that predicts overall survival in diffuse malignant peritoneal Mesothelioma with epithelioid subtype. Am J Surg Pathol 40:1243\u20131248","journal-title":"Am J Surg Pathol"},{"key":"1317_CR9","unstructured":"Husain AN, Chapel DB, Attanoos A et al Guidelines for the pathologic diagnosis of mesothelioma. 2023 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med, in press"},{"key":"1317_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.humpath.2020.04.005","volume":"100","author":"JR Naso","year":"2020","unstructured":"Naso\u00a0JR, Churg\u00a0A (2020) Claudin\u20114 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4. Hum Pathol 100:10\u201314","journal-title":"Hum Pathol"},{"key":"1317_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/his.14783","volume":"82","author":"A Churg","year":"2023","unstructured":"Churg\u00a0A, Naso\u00a0JR (2023) Hypothesis: HEG1 and claudin\u20114 staining will allow a\u00a0diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases. Histopathology 82:385\u2013392","journal-title":"Histopathology"},{"key":"1317_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/modpathol.2009.180","volume":"23","author":"S Klebe","year":"2010","unstructured":"Klebe\u00a0S, Brownlee\u00a0NA, Mahar\u00a0A et\u00a0al (2010) Sarcomatoid mesothelioma: a\u00a0clinical-pathologic correlation of 326 cases. Mod Pathol 23:470\u2013479","journal-title":"Mod Pathol"},{"key":"1317_CR13","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1097\/PAS.0000000000001565","volume":"44","author":"A Churg","year":"2020","unstructured":"Churg\u00a0A, Naso\u00a0JR (2020) The separation of benign and malignant mesothelial proliferations: new markers and how to use them. Am J Surg Pathol 44:e100\u2013e112","journal-title":"Am J Surg Pathol"},{"issue":"35","key":"1317_CR14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s41379-022-01081-z","volume":"2022","author":"DB Chapel","year":"2022","unstructured":"Chapel\u00a0DB, Hornick\u00a0JL, Barlow\u00a0J et\u00a0al (2022) Clinical and molecular validation of BAP1, MTAP, P53, and merlin immunohistochemistry in diagnosis of pleural mesothelioma. Mod Pathol 2022(35):1383\u20131397","journal-title":"Mod Pathol"},{"key":"1317_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41379-021-00920-9","volume":"35","author":"JR Naso","year":"2022","unstructured":"Naso\u00a0JR, Tessier-Cloutier\u00a0B, Senz\u00a0J et\u00a0al (2022) Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status. Mod Pathol 35:77\u201381","journal-title":"Mod Pathol"},{"key":"1317_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41379-019-0347-0","volume":"33","author":"A Churg","year":"2020","unstructured":"Churg\u00a0A, Galateau-Salle\u00a0F, Roden\u00a0AC et\u00a0al (2020) Malignant mesothelioma in situ: morphologic features and clinical outcome. Mod Pathol 33:297\u2013302","journal-title":"Mod Pathol"},{"key":"1317_CR17","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41379-022-01082-y","volume":"35","author":"A Churg","year":"2022","unstructured":"Churg\u00a0A, Galateau-Salle\u00a0F (2022) Well differentiated papillary mesothelial tumor: a\u00a0new name and new problems. Mod Pathol 35:1327\u20131333","journal-title":"Mod Pathol"},{"key":"1317_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00428-022-03281-z","volume":"481","author":"M Nishikubo","year":"2022","unstructured":"Nishikubo\u00a0M, Jimbo\u00a0N, Tanaka\u00a0Y et\u00a0al (2022) Sarcomatoid mesothelioma originating from mesothelioma in situ: are methylthioadenosine phosphorylase loss and CDKN2A homozygous deletion poor prognostic factors for preinvasive mesothelioma? Virchows Arch 481:307\u2013312","journal-title":"Virchows Arch"}],"container-title":["Die Pathologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-024-01317-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-024-01317-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-024-01317-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T21:21:32Z","timestamp":1724448092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-024-01317-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1317"],"URL":"https:\/\/doi.org\/10.1007\/s00292-024-01317-6","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"assertion":[{"value":"14 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.\u00a0Churg declares that he has no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}